Business Context and Reporting Period
This Form 8-K is a current report filed by WellPoint, Inc. (now Elevance Health, Inc.) on December 11, 2012. The filing serves as Regulation FD disclosure regarding upcoming meetings with securities analysts and investors scheduled between December 11, 2012, and December 19, 2012. The primary purpose is to reaffirm the company's financial guidance for the full year 2012 and provide an outlook for 2013.
Key Financial Metrics and Guidance
WellPoint reaffirmed its full-year 2012 earnings per share (EPS) guidance. The filing details the following ranges:
- Net Income per Diluted Share: $7.37 to $7.47
- Adjusted Net Income per Diluted Share: $7.30 to $7.40
The adjusted net income excludes specific items totaling a net positive contribution of $0.07 per share. These items include:
- Net realized gains on investments (first nine months): $(0.70)
- Other-than-temporary impairment losses (first nine months): $0.06
- Litigation related costs: $0.07
- Acquisition and integration costs (including Q4): $0.21
- Tax effect of adjustments: $0.29
The filing does not provide specific values for total revenue, operating cash flow, total debt, or liquidity ratios for the period.
Material Changes and Outlook
For the 2013 fiscal year, management expects adjusted net income to be relatively stable compared to 2012. This outlook includes the anticipated impact of the Amerigroup Corporation acquisition, which was expected to close in December 2012. The 2012 guidance ranges explicitly do not reflect the financial impact of the Amerigroup acquisition closing or any investment gains/losses beyond those recorded through September 30, 2012.
Management Commentary, Risks, and Unusual Items
Executive Transactions: An annual vesting of equity-based compensation awards occurred on December 10, 2012. Additionally, CFO Wayne S. DeVeydt and Controller John E. Gallina are anticipated to sell stock pursuant to Rule 10b5-1 plans.
Risks and Contingencies: The filing includes a comprehensive Safe Harbor statement identifying significant risks, including:
- Regulatory changes under the Patient Protection and Affordable Care Act.
- Challenges in securing premium rates and contracting with providers.
- Risks associated with the Amerigroup and 1-800 CONTACTS acquisitions, including integration difficulties and synergy realization.
- Exposure to Medicare and Medicaid funding risks and compliance issues.
- Potential litigation, medical malpractice claims, and data security breaches.
- Market conditions affecting investment portfolios and liquidity.
Investor Verification Checklist
- Verify the actual closing date and financial impact of the Amerigroup Corporation acquisition.
- Confirm the final full-year 2012 net income and adjusted net income against the reaffirmed guidance ranges.
- Review subsequent filings for updates on the integration of Amerigroup and 1-800 CONTACTS.
- Monitor regulatory developments regarding the Affordable Care Act and their impact on premium rates.
- Check for any material changes in litigation costs or investment impairments not captured in the Q3 data.